多帕菲联合铂类治疗复发转移性卵巢癌58例临床分析  

Clinical study of docetaxel combined with platinum for treatment of 58 cases recurrent ovarian carcinoma

作　　者：杨悦[1] 

机构地区：[1]浙江省肿瘤医院妇科,浙江杭州310022

出　　处：《中华肿瘤防治杂志》2008年第15期1176-1177,共2页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:探讨多帕菲联合铂类治疗复发卵巢癌的近期疗效和毒副反应。方法:多帕菲75mg/m2,静脉滴入1h,d1;铂尔定按Auc为5,根据体表面积肌酐清除率计算,d1;每周期间隔21～28d,至少应用2周期。结果:完全缓解22例,部分缓解19例,总有效率为70.7%(41/58)。毒副反应主要表现为轻和中度的骨髓抑制、恶心、呕吐及脱发等。结论:多帕菲联合铂类治疗复发卵巢癌有较好的近期疗效,毒副反应较小,临床上可以接受。OBJECTIVE： To evaluate the efficacy and side effects of docetaxel combined with platinum in the treatment of re current ovarian carcinoma. METHODS： Fifty-eight cases of recurrent ovarian carcinoma were treated with docetaxel 75 mg/m^2 iv, d1, and carboplatin AUC .5 d1 , and the repeat courses were conducted with an interval 21 to 28 days. All the patients were evaluated for the response. RESULTS：The total response rate （CR＋PR） was 70.7%（CR=22, PR=19）. The side effects were mild, inclu ding myelosuppression, nausea and vomiting. CONCLUSIONS： The combination chemotherapy of docetaxel plus platinum is a safe and effective regimen for patients with recurrent ovarian carcinoma.

关 键 词：卵巢肿瘤/药物疗法 化疗 多帕菲 铂类 

分 类 号：R737.31[医药卫生—肿瘤]